Search | VHL Search Portal

Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer.

Shapiro, Lauren C; Thakkar, Astha; Campbell, Sean T; Forest, Stefanie K; Pradhan, Kith; Gonzalez-Lugo, Jesus D; Quinn, Ryann; Bhagat, Tushar D; Choudhary, Gaurav S; McCort, Margaret; Sica, R Alejandro; Goldfinger, Mendel; Goel, Swati; Anampa, Jesus D; Levitz, David; Fromowitz, Ariel; Shah, Akash Pradip; Sklow, Charlotte; Alfieri, Gregory; Racine, Andrew; Wolgast, Lucia; Greenberger, Lee; Verma, Amit; Halmos, Balazs.

Cancer Cell ; 40(1): 3-5, 2022 01 10.

Article in English | MEDLINE | ID: mdl-34838186

ABSTRACT

Anti-COVID-19 immunity dynamics were assessed in patients with cancer in a prospective clinical trial. Waning of immunity was detected 4-6 months post-vaccination with significant increases in anti-spike IgG titers after booster dosing, and 56% of seronegative patients seroconverted post-booster vaccination. Prior anti-CD20/BTK inhibitor therapy was associated with reduced vaccine efficacy.

Subject(s)

Antibodies, Viral/biosynthesis , COVID-19 Vaccines/immunology , COVID-19/prevention & control , Immunization, Secondary , Immunoglobulin G/biosynthesis , Neoplasms/immunology , SARS-CoV-2/immunology , Agammaglobulinaemia Tyrosine Kinase/antagonists & inhibitors , Antibodies, Viral/blood , Antibodies, Viral/immunology , Antigens, Viral/immunology , COVID-19/complications , COVID-19/immunology , Follow-Up Studies , Humans , Immunocompromised Host , Immunogenicity, Vaccine , Immunoglobulin G/blood , Immunoglobulin G/immunology , Neoplasms/complications , Neoplasms/drug therapy , Prospective Studies , Protein Kinase Inhibitors/adverse effects , Protein Kinase Inhibitors/therapeutic use , Rituximab/adverse effects , Rituximab/therapeutic use , Seroconversion , Spike Glycoprotein, Coronavirus/immunology , Vaccination

ABSTRACT

Subject(s)

SEND TO:

SELECTION OF CITATIONS

SEARCH DETAIL